In the last two decades, targeted therapy has significantly improved the prognosis of melanoma with BRAF mutation, with vemurafenib and dabrafenib being approved by United States Food and Drug Administration (US FDA) [17, 18]. The gene discussed is BRAF; the disease is melanoma.